Nowicki A, Ostrowska G, Aukerman S L, Wiktor-Jedrzejczak W
Regional Center of Oncology, Poland.
Arch Immunol Ther Exp (Warsz). 1994;42(4):313-7.
C57Bl/6 mice, bearing transplantable Lewis lung cancer (non-metastatic subline) implanted either subcutaneously or intraperitoneally were treated with macrophage colony stimulating factor (M-CSF, 10(6) units per mouse, per day for 19 days), Escherichia coli lipopolysaccharide or both. Lipopolysaccharide (5 micrograms per mouse) administered daily once a day for up to 30 days impaired both subcutaneous and intraperitoneal tumor growth and prolonged survival of tumor bearing mice. Macrophage colony stimulating factor, administered daily, inhibited only subcutaneous tumor growth, both when administered alone and in combination with with lipopolysaccharide, and had no effect on intraperitoneal tumor. Moreover, it did not prolong survival of tumor bearing mice, when administered alone, and nullified the effects of lipopolysaccharide when administered concomitantly. These data suggest that macrophage colony stimulating factor, at least in this tumor model and in this dose schedule, offers little benefit. In contrast, the present data confirm earlier suggestions on therapeutic usefulness of bacterial lipopolysaccharide in neoplastic disease, which makes this compound an interesting candidate for future clinical trials.
将可移植的Lewis肺癌（非转移性亚系）皮下或腹腔内植入的C57Bl/6小鼠，用巨噬细胞集落刺激因子（M-CSF，每只小鼠每天10^6单位，共19天）、大肠杆菌脂多糖或两者进行处理。每天一次给予脂多糖（每只小鼠5微克），持续30天，可抑制皮下和腹腔内肿瘤的生长，并延长荷瘤小鼠的生存期。每天给予巨噬细胞集落刺激因子，无论是单独给药还是与脂多糖联合给药，都仅抑制皮下肿瘤的生长，对腹腔内肿瘤无影响。此外，单独给药时它不会延长荷瘤小鼠的生存期，与脂多糖同时给药时会抵消脂多糖的作用。这些数据表明，至少在这个肿瘤模型和这个剂量方案中，巨噬细胞集落刺激因子益处不大。相比之下，目前的数据证实了早期关于细菌脂多糖在肿瘤疾病中治疗作用的观点，这使得该化合物成为未来临床试验的一个有趣候选药物。
